Denosumab Intas: Uses, Dosage & Side Effects
A RANK ligand inhibitor monoclonal antibody for the treatment of osteoporosis and prevention of skeletal-related events in adults at increased risk of fractures
Denosumab Intas is a prescription biosimilar monoclonal antibody containing denosumab as its active substance. It is used primarily for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, as well as for the treatment of bone loss associated with hormone ablation therapy in patients with cancer. Denosumab works by targeting and inhibiting RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast formation, function, and survival. By blocking RANKL, denosumab reduces bone resorption, increases bone mineral density, and significantly reduces the risk of vertebral, non-vertebral, and hip fractures. It is administered as a subcutaneous injection of 60 mg once every 6 months by a healthcare professional.
Quick Facts: Denosumab Intas
Key Takeaways
- Denosumab Intas is a biosimilar of the reference product Prolia, containing the same active substance (denosumab 60 mg) with demonstrated equivalent efficacy, safety, and quality through comprehensive comparative studies.
- It is administered as a single subcutaneous injection of 60 mg once every 6 months, making it one of the most convenient osteoporosis treatment options available, and is given by a healthcare professional.
- Clinical trials have demonstrated that denosumab reduces the risk of vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% in postmenopausal women with osteoporosis.
- All patients receiving Denosumab Intas must take adequate calcium (at least 1,000 mg daily) and vitamin D (at least 400 IU daily) supplementation, and hypocalcemia must be corrected before initiating treatment.
- Treatment should not be stopped without medical advice, as discontinuation leads to rapid bone loss and increased fracture risk; transition to an alternative anti-resorptive therapy should be considered if denosumab is discontinued.
What Is Denosumab Intas and What Is It Used For?
Denosumab Intas contains the active substance denosumab, a fully human monoclonal antibody of the immunoglobulin G2 (IgG2) subclass produced in genetically engineered Chinese hamster ovary (CHO) cells using recombinant DNA technology. As a biosimilar medicine, Denosumab Intas has been developed to be highly similar to the reference product Prolia (manufactured by Amgen), which was first approved by the European Medicines Agency (EMA) in 2010 and the U.S. Food and Drug Administration (FDA) in the same year. The biosimilar designation means that Denosumab Intas has undergone rigorous comparative analytical, non-clinical, and clinical studies to demonstrate equivalent quality, safety, and efficacy to the reference product.
Denosumab works through a highly specific mechanism of action targeting the RANK/RANKL/OPG signaling pathway, which is the central regulatory system for bone remodeling. Under normal physiological conditions, bone is continuously being broken down (resorbed) by osteoclasts and rebuilt by osteoblasts in a balanced process known as bone remodeling. Receptor activator of nuclear factor kappa-B ligand (RANKL) is a transmembrane protein expressed by osteoblasts and osteocytes that binds to its receptor RANK on the surface of osteoclast precursor cells and mature osteoclasts. This RANKL-RANK interaction is essential for the formation, activation, and survival of osteoclasts. In conditions such as osteoporosis, postmenopausal estrogen deficiency, and glucocorticoid excess, RANKL production is upregulated, leading to excessive osteoclast activity and net bone loss.
Denosumab mimics the action of osteoprotegerin (OPG), the natural decoy receptor for RANKL. By binding to RANKL with high affinity and specificity, denosumab prevents RANKL from activating RANK on osteoclast surfaces. This effectively inhibits osteoclast differentiation from precursor cells, suppresses the bone-resorbing activity of mature osteoclasts, and promotes osteoclast apoptosis (programmed cell death). The result is a rapid, sustained, and reversible reduction in bone resorption, accompanied by increases in bone mineral density (BMD) at all skeletal sites, including the lumbar spine, total hip, femoral neck, and distal radius.
Denosumab Intas is indicated for several clinical conditions where reducing bone resorption provides significant clinical benefit:
- Postmenopausal osteoporosis: Treatment of osteoporosis in postmenopausal women at increased risk of fractures. Denosumab reduces the risk of vertebral, non-vertebral, and hip fractures. This is the primary indication and the one supported by the most extensive clinical data.
- Male osteoporosis: Treatment of bone loss in men with osteoporosis who are at increased risk of fractures. Men account for approximately 20–25% of all osteoporotic fractures, and denosumab has been shown to significantly increase BMD in men with primary or hypogonadal osteoporosis.
- Cancer treatment-induced bone loss: Treatment of bone loss associated with hormone ablation therapy in men with prostate cancer at increased risk of fractures, and treatment of bone loss in women receiving aromatase inhibitor therapy for breast cancer at increased risk of fractures.
- Glucocorticoid-induced osteoporosis: Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
The pivotal evidence for the efficacy of denosumab in postmenopausal osteoporosis comes from the landmark FREEDOM trial (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months). This randomized, double-blind, placebo-controlled trial enrolled 7,868 postmenopausal women aged 60–90 years with osteoporosis. Over 3 years of treatment, denosumab 60 mg every 6 months demonstrated statistically significant and clinically meaningful reductions in fracture risk compared with placebo: a 68% reduction in new vertebral fractures (relative risk 0.32, 95% CI 0.26–0.41), a 40% reduction in hip fractures (hazard ratio 0.60, 95% CI 0.37–0.97), and a 20% reduction in non-vertebral fractures (hazard ratio 0.80, 95% CI 0.67–0.95). The FREEDOM Extension study followed patients for up to 10 years, demonstrating continued increases in BMD and sustained low fracture rates with long-term treatment, as well as a favorable long-term safety profile.
In the ADAMO trial (A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Denosumab in the Treatment of Male Osteoporosis), denosumab significantly increased BMD at the lumbar spine, total hip, femoral neck, and distal third radius in men with osteoporosis, with effects comparable to those observed in postmenopausal women. For cancer treatment-induced bone loss, the HALT prostate cancer trial demonstrated that denosumab reduced the incidence of new vertebral fractures by 62% in men receiving androgen deprivation therapy, while a similar trial in women receiving aromatase inhibitors showed significant preservation of BMD.
Denosumab Intas has been approved as a biosimilar following the rigorous EMA biosimilar guidelines. This means it has been demonstrated through comprehensive analytical characterization, functional assays, and clinical studies to have equivalent quality, safety, and efficacy compared to the reference product Prolia. Patients can be confident that Denosumab Intas provides the same therapeutic benefit as the originator product.
What Should You Know Before Taking Denosumab Intas?
Contraindications
Denosumab Intas must not be used in patients with known hypersensitivity to denosumab or to any of the excipients. Although rare, serious allergic reactions including anaphylaxis have been reported with denosumab products. Denosumab Intas is also contraindicated in patients with pre-existing hypocalcemia. Hypocalcemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. This is a critical safety requirement because denosumab’s potent inhibition of bone resorption reduces calcium release from the skeleton, which can exacerbate existing hypocalcemia and lead to serious complications including cardiac arrhythmias, seizures, muscle spasms, and tetany.
Before starting Denosumab Intas, your healthcare provider should perform a thorough medical assessment including measurement of serum calcium, 25-hydroxyvitamin D, creatinine, and phosphate levels. Patients with conditions that predispose to hypocalcemia (such as hypoparathyroidism, previous thyroid or parathyroid surgery, malabsorption syndromes, or excision of the small intestine) require particularly close monitoring. Serum calcium should be monitored within 2 weeks after the initial dose in patients predisposed to hypocalcemia, and periodically thereafter.
Warnings and Precautions
Osteonecrosis of the jaw (ONJ): ONJ is a recognized adverse effect of anti-resorptive therapy, including denosumab. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery are possible signs of ONJ. Risk factors include invasive dental procedures (such as tooth extraction, dental implants, oral surgery), poor oral hygiene, use of dentures, concomitant therapies (corticosteroids, chemotherapy, angiogenesis inhibitors), pre-existing dental conditions, and smoking. A dental examination with appropriate preventive dentistry should be considered prior to treatment with Denosumab Intas. During treatment, patients should maintain good oral hygiene and receive routine dental check-ups. Invasive dental procedures should be avoided if possible, and if required, should be planned in consultation with the prescribing physician.
Atypical femoral fractures: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with denosumab, although they are rare. These fractures may occur with minimal or no trauma and may be bilateral. Patients may experience prodromal symptoms such as new or unusual thigh, hip, or groin pain weeks to months before a complete fracture occurs. If such symptoms develop, patients should be evaluated promptly for an incomplete femoral fracture. Discontinuation of denosumab therapy should be considered on an individual basis, weighing the benefits and risks of continued treatment.
Infections: In clinical trials, infections leading to hospitalization, including skin infections (predominantly cellulitis), were reported more frequently in the denosumab group compared with placebo. Patients receiving concomitant immunosuppressive therapy or with conditions that impair the immune system may be at increased risk. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of cellulitis or other infections.
Skin reactions: Dermatitis, eczema, and rashes have been reported with denosumab. Most skin reactions are mild to moderate, but severe cases including rare instances of dermatitis resulting in hospitalization have occurred. If severe skin reactions develop, treatment discontinuation should be considered.
Discontinuation of denosumab without transition to an alternative anti-resorptive therapy (such as a bisphosphonate) has been associated with a rapid rebound increase in bone turnover markers to levels above pre-treatment values, rapid loss of bone mineral density to approximately pre-treatment levels within 12–18 months, and a significantly increased risk of multiple vertebral fractures. If you and your doctor decide to stop treatment, an alternative osteoporosis therapy should be discussed and initiated.
Pregnancy and Breastfeeding
Denosumab Intas is not recommended during pregnancy. There are no adequate data from the use of denosumab in pregnant women. Animal studies have demonstrated reproductive toxicity, including skeletal abnormalities in offspring (including absent peripheral lymph nodes, abnormal bone growth, reduced bone strength, and reduced neonatal growth), as well as increased stillbirth and postnatal mortality. Women of childbearing potential should use effective contraception during treatment and for at least 5 months after the last dose of Denosumab Intas.
It is not known whether denosumab is excreted in human breast milk. However, because genetically engineered antibodies (such as denosumab) may be excreted in milk and because of the potential for adverse effects on the breastfed infant (including bone metabolism effects), a decision should be made whether to discontinue breastfeeding or to discontinue Denosumab Intas therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Breastfeeding is generally not recommended during treatment with Denosumab Intas.
Fertility: There are no data on the effect of denosumab on human fertility. Animal studies showed no adverse effects on female fertility. However, in animal studies with long-term exposure to denosumab, temporary effects on fertility were observed, which resolved after cessation of treatment.
How Does Denosumab Intas Interact with Other Drugs?
Because denosumab is a fully human IgG2 monoclonal antibody, it is catabolized via general protein degradation pathways rather than hepatic cytochrome P450 (CYP) enzymes. This means that denosumab does not inhibit, induce, or compete with CYP-mediated drug metabolism, and traditional pharmacokinetic drug-drug interactions (such as those commonly seen with small-molecule drugs) are not expected. No formal drug interaction studies have been conducted with Denosumab Intas, but extensive clinical experience with the reference product across multiple large-scale trials involving thousands of patients has not revealed clinically significant pharmacokinetic interactions.
Nevertheless, there are several important pharmacodynamic interactions and clinical considerations that prescribers and patients should be aware of:
| Drug / Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Bisphosphonates (alendronate, risedronate, zoledronic acid) | Pharmacodynamic – additive anti-resorptive effect | Concurrent use has not been studied and may increase risk of hypocalcemia and over-suppression of bone turnover | Avoid concurrent use; bisphosphonates may be used sequentially after denosumab discontinuation |
| Immunosuppressants (corticosteroids, methotrexate, cyclosporine) | Pharmacodynamic – additive immunosuppression | Increased risk of serious infections, particularly skin infections (cellulitis) | Use with caution; monitor for signs of infection |
| Other monoclonal antibodies (e.g., romosozumab) | Pharmacodynamic – dual bone pathway modulation | Sequential use (romosozumab followed by denosumab) has been studied; concurrent use data limited | Sequential use may be appropriate under specialist guidance; avoid concurrent use |
| Calcium and vitamin D supplements | Supportive therapy | Essential co-administration; denosumab reduces calcium release from bone | All patients must take adequate calcium (≥1,000 mg/day) and vitamin D (≥400 IU/day) |
| Angiogenesis inhibitors (bevacizumab, sunitinib) | Additive risk factor | Increased risk of osteonecrosis of the jaw (ONJ) | Enhanced dental monitoring; dental assessment before treatment initiation |
Major Interactions
The most clinically significant interaction concern involves the concurrent use of denosumab with bisphosphonates. Both drug classes inhibit osteoclast-mediated bone resorption through different mechanisms, and their combined use could theoretically lead to over-suppression of bone turnover, increased risk of hypocalcemia, and potentially a higher risk of rare complications such as osteonecrosis of the jaw or atypical femoral fractures. Current clinical guidelines uniformly recommend against simultaneous use of denosumab and bisphosphonates. However, sequential use is an important clinical strategy: bisphosphonates are frequently initiated after denosumab discontinuation to prevent the rebound bone loss that occurs when denosumab treatment is stopped.
Concurrent immunosuppressive therapy warrants careful consideration. In the FREEDOM trial, serious infections (including those requiring hospitalization) were observed at a higher rate in the denosumab group (3.7%) versus placebo (3.2%). RANKL is expressed not only on osteoblasts but also on activated T cells and dendritic cells, where it plays a role in immune cell communication. Inhibition of RANKL may therefore have subtle effects on immune surveillance, although the clinical significance of this in immunocompetent patients appears minimal.
Minor Interactions
Denosumab does not appear to interact significantly with commonly used medications including antihypertensives, statins, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs), or oral diabetes medications. In clinical trials, denosumab was used in patients taking a wide variety of concomitant medications without evidence of clinically meaningful interactions. Hormonal therapies including estrogen replacement therapy and selective estrogen receptor modulators (SERMs) such as raloxifene have been used concurrently with denosumab in clinical practice, though the benefit of adding denosumab to these therapies has not been established in large randomized trials.
Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting Denosumab Intas. While traditional pharmacokinetic interactions are unlikely, the pharmacodynamic considerations noted above are clinically important.
What Is the Correct Dosage of Denosumab Intas?
Denosumab Intas is supplied as a ready-to-use solution for injection in a pre-filled syringe containing 60 mg of denosumab in 1 mL. The fixed-dose regimen of 60 mg every 6 months is the same for all approved indications and does not require adjustment based on body weight, age, sex, or renal function. This simplicity of dosing is one of the practical advantages of denosumab therapy, as it eliminates the need for complex dose calculations or therapeutic drug monitoring.
Adults
Postmenopausal Osteoporosis
60 mg subcutaneously once every 6 months. Ensure adequate calcium (≥1,000 mg/day) and vitamin D (≥400 IU/day) supplementation. Treatment duration should be reassessed periodically; long-term use (beyond 5–10 years) should be evaluated on an individual basis weighing fracture risk against potential long-term safety considerations.
Male Osteoporosis
60 mg subcutaneously once every 6 months. Same dosing regimen as for postmenopausal women. Men with osteoporosis should receive calcium and vitamin D supplements alongside treatment. Testosterone replacement should be considered separately if hypogonadism is a contributing factor.
Cancer Treatment-Induced Bone Loss
60 mg subcutaneously once every 6 months. Used in men with prostate cancer receiving androgen deprivation therapy and women with breast cancer receiving aromatase inhibitor therapy who are at increased risk of fracture. Calcium and vitamin D supplementation is mandatory.
Glucocorticoid-Induced Osteoporosis
60 mg subcutaneously once every 6 months. For adult patients on long-term systemic glucocorticoid therapy (≥7.5 mg/day prednisone equivalent for ≥3 months) at increased risk of fracture. Calcium and vitamin D supplementation is required.
Children
Denosumab Intas (60 mg) is not approved for use in children and adolescents under 18 years of age. The safety and efficacy of denosumab at the 60 mg dose have not been established in the pediatric population. Denosumab at higher doses (120 mg, marketed under a different brand name for oncology indications) has been studied in adolescents with giant cell tumor of bone, but this is a different indication, dose, and product. The potential impact of RANKL inhibition on the growing skeleton remains a concern, as RANKL plays important roles in bone modeling during growth, immune system development, and dental development.
Elderly
No dose adjustment is required for elderly patients. In the FREEDOM trial, approximately 33% of patients were aged 75 years or older, and the efficacy and safety profile of denosumab was consistent across age groups. There was no increased incidence of adverse events in elderly patients compared with younger patients. Denosumab is particularly advantageous in elderly patients because its subcutaneous administration every 6 months avoids the gastrointestinal issues associated with oral bisphosphonates and the complexity of intravenous administration required for zoledronic acid.
Renal impairment: No dose adjustment is required for patients with renal impairment, including those with severe renal impairment (creatinine clearance <30 mL/min) or those receiving dialysis. However, patients with severe renal impairment or on dialysis are at greater risk of hypocalcemia due to impaired vitamin D metabolism and reduced renal calcium handling. These patients require more intensive monitoring of calcium levels and may need higher doses of calcium and vitamin D supplements.
Missed Dose
If a dose of Denosumab Intas is missed or delayed, the injection should be administered as soon as possible. Thereafter, injections should be scheduled every 6 months from the date of the last injection. Clinical data suggest that the anti-resorptive effects of denosumab begin to wane within approximately 6 months of the last injection, so adherence to the 6-monthly dosing schedule is important to maintain continuous fracture protection. If a dose is significantly delayed (more than 1–2 months beyond the scheduled date), bone turnover markers will begin to rise, and bone density gains may partially reverse. Timely re-dosing restores the anti-resorptive effect.
Overdose
There is no specific experience with acute overdose of denosumab in clinical trials. In clinical development, denosumab has been administered at doses up to 180 mg every 4 weeks (3 times the recommended dose and at 50% more frequent intervals) without dose-limiting toxicity. There is no specific antidote for denosumab overdose. In the event of overdose, the patient should be monitored for signs and symptoms of hypocalcemia, and appropriate supportive care should be provided, including calcium supplementation if needed.
What Are the Side Effects of Denosumab Intas?
The safety profile of denosumab has been extensively characterized through large-scale randomized controlled trials, their long-term extension studies, and extensive post-marketing surveillance. The FREEDOM trial and its 10-year extension involved over 7,800 women, providing robust long-term safety data. Overall, denosumab has a well-established and generally favorable safety profile, with the majority of adverse effects being mild to moderate in severity.
The following side effects have been reported with denosumab products and may occur with Denosumab Intas. Side effects are categorized by frequency according to the internationally recognized MedDRA convention:
Very Common
Affects more than 1 in 10 patients (>10%)
- Musculoskeletal pain (back pain, pain in extremity, bone pain, musculoskeletal pain)
Common
Affects 1 to 10 in 100 patients (1–10%)
- Urinary tract infection
- Upper respiratory tract infection (nasopharyngitis, pneumonia)
- Sciatica
- Constipation
- Abdominal pain
- Skin rash
- Eczema
- Limb pain
- Cataracts (in patients receiving cancer treatment)
Uncommon
Affects 1 to 10 in 1,000 patients (0.1–1%)
- Cellulitis (skin infection)
- Ear infection
- Diverticulitis
- Hypocalcemia (low blood calcium)
- Dental infections/extraction-related complications
Rare
Affects 1 to 10 in 10,000 patients (0.01–0.1%)
- Osteonecrosis of the jaw (ONJ)
- Atypical femoral fractures
- Hypersensitivity reactions (rash, urticaria, facial swelling)
- Anaphylaxis
Not Known
Frequency cannot be estimated from the available data
- Osteonecrosis of the external auditory canal
- Musculoskeletal pain (including severe cases)
Musculoskeletal pain is the most frequently reported adverse effect of denosumab, encompassing a range of symptoms including back pain, pain in the arms or legs, and generalized bone or muscle pain. In the FREEDOM trial, musculoskeletal pain was reported by approximately 26% of denosumab-treated patients compared with 25% of placebo-treated patients, suggesting that the baseline rate is high in this patient population. However, post-marketing reports have identified cases of severe musculoskeletal pain, sometimes with onset days to months after initiating denosumab, that warranted medical attention.
Infections, particularly of the urinary tract and upper respiratory system, were observed at slightly higher rates in denosumab-treated patients in clinical trials. Serious infections leading to hospitalization, including skin infections (predominantly cellulitis and erysipelas), abdominal and urinary tract infections, and endocarditis, were reported in 3.7% of denosumab patients versus 3.2% of placebo patients in the FREEDOM trial. Although RANKL has known roles in the immune system, a definitive causal relationship between denosumab and increased infection risk has not been established, and the magnitude of any potential increase appears small.
Hypocalcemia is an expected pharmacological consequence of potent anti-resorptive therapy. In clinical trials, decreases in serum calcium below 8.5 mg/dL were observed in approximately 0.4% of denosumab-treated patients. Clinically significant hypocalcemia requiring medical intervention is uncommon when patients receive adequate calcium and vitamin D supplementation, but it is more likely in patients with severe renal impairment, those on dialysis, and those with conditions predisposing to hypocalcemia.
Contact your healthcare provider immediately if you experience: signs of hypocalcemia (muscle cramps, numbness or tingling in fingers, toes, or around the mouth, muscle spasms); symptoms of infection (fever, chills, redness or swelling of the skin, painful urination); persistent jaw pain, numbness, or swelling; unusual pain in the thigh, hip, or groin; or signs of allergic reaction (difficulty breathing, swelling of the face or throat, skin rash with itching).
How Should You Store Denosumab Intas?
Proper storage of Denosumab Intas is essential to maintain the stability, potency, and safety of the biological product. As a protein-based monoclonal antibody, denosumab is sensitive to temperature extremes, physical agitation, and light exposure, all of which can lead to protein denaturation, aggregation, or loss of biological activity.
The recommended storage conditions for Denosumab Intas are as follows:
- Refrigerated storage: Store at 2–8°C (36–46°F) in a refrigerator. This is the primary long-term storage condition.
- Do not freeze: Freezing can cause irreversible damage to the protein structure of the monoclonal antibody. If the product has been frozen, it should not be used and should be discarded.
- Protect from light: Keep the pre-filled syringe in the original outer carton until ready for use to protect the solution from light exposure.
- Room temperature allowance: Before administration, Denosumab Intas may be removed from the refrigerator and allowed to reach room temperature (up to 25°C / 77°F) over approximately 15–30 minutes. This helps reduce injection site discomfort. Do not warm by any other means (such as microwave or hot water).
- Do not shake: Vigorous shaking can cause protein aggregation and foaming, which may reduce the biological activity of the product and increase the risk of immunogenic reactions.
- Shelf life: Refer to the expiry date on the carton and syringe label. Do not use Denosumab Intas after the expiry date.
- Visual inspection: Before administration, visually inspect the solution. It should appear clear, colorless to slightly yellow. Do not use if the solution is cloudy, discolored, or contains visible particles.
Keep Denosumab Intas out of the sight and reach of children. Do not dispose of used syringes in household waste. Used syringes should be placed in a sharps disposal container and disposed of in accordance with local regulations. Your healthcare provider will typically handle the administration and disposal of the pre-filled syringe.
What Does Denosumab Intas Contain?
Denosumab Intas is a clear, colorless to slightly yellow solution provided in a single-use, pre-filled syringe. Understanding the composition of the product is important for healthcare providers assessing potential allergenic components and for patients with known sensitivities to specific excipients.
Active Ingredient
The active ingredient is denosumab, a fully human immunoglobulin G2 (IgG2) monoclonal antibody with a molecular weight of approximately 147 kDa. Each pre-filled syringe contains 60 mg of denosumab in 1 mL of solution (60 mg/mL concentration). Denosumab is produced by recombinant DNA technology in genetically engineered Chinese hamster ovary (CHO) cells and undergoes extensive purification processes to ensure high purity and consistency.
Inactive Ingredients (Excipients)
The formulation contains the following excipients, which serve as stabilizers, buffers, and surfactants to maintain the structural integrity and biological activity of the monoclonal antibody:
- Acetic acid, glacial: Used as a buffering agent to maintain the pH of the solution within the optimal range for protein stability.
- Sodium hydroxide: Used for pH adjustment to achieve the target formulation pH.
- Sorbitol (E420): A sugar alcohol used as a stabilizer and tonicity agent that helps protect the protein from denaturation during storage.
- Polysorbate 20: A non-ionic surfactant that prevents protein aggregation and adsorption to container surfaces, thereby maintaining the biological activity of denosumab.
- Water for injections: The solvent vehicle for the formulation.
Denosumab Intas does not contain preservatives, latex (in the syringe components), or any components derived from animal sources other than the CHO cell line used for production. Patients with known hypersensitivity to any of the listed excipients should inform their healthcare provider before receiving the injection.
Frequently Asked Questions About Denosumab Intas
Denosumab Intas is a biosimilar of Prolia. Both products contain the same active substance (denosumab 60 mg), are administered at the same dose and frequency (60 mg subcutaneously every 6 months), and are used for the same indications. A biosimilar is a biological medicine that has been shown through comprehensive analytical, non-clinical, and clinical studies to be highly similar to an already approved reference product with no clinically meaningful differences in terms of quality, safety, or efficacy. The main difference may be in the manufacturing process and price, as biosimilars typically offer a more affordable alternative to the originator product.
The duration of treatment should be determined by your doctor based on your individual fracture risk and response to therapy. Current clinical guidelines suggest that most patients benefit from at least 5 years of denosumab therapy, with reassessment at that point. Patients who remain at high fracture risk may benefit from continued treatment beyond 5 years; the FREEDOM Extension study demonstrated continued efficacy and an acceptable safety profile for up to 10 years. It is critically important that you do not stop treatment without discussing this with your doctor, as abrupt discontinuation can lead to rapid bone loss and an increased risk of vertebral fractures.
Routine dental care including check-ups, cleanings, and fillings can generally continue during treatment with Denosumab Intas. However, invasive dental procedures such as tooth extractions, dental implants, or oral surgery may increase the risk of osteonecrosis of the jaw (ONJ), a rare but serious complication. You should inform your dentist that you are taking Denosumab Intas before any dental procedure. If possible, necessary invasive dental work should be completed before starting treatment. If invasive dental procedures are required during treatment, your doctor and dentist should coordinate care to minimize risk.
Denosumab works by strongly inhibiting bone resorption, which reduces the release of calcium from the skeleton into the bloodstream. Without adequate calcium and vitamin D intake, this reduction in calcium release can lead to hypocalcemia (low blood calcium), which can cause symptoms such as muscle cramps, tingling, and in severe cases, seizures or cardiac problems. Calcium supplementation (at least 1,000 mg per day) provides the body with the calcium it needs, while vitamin D (at least 400 IU per day) ensures proper calcium absorption from the gut. Your doctor may recommend higher doses based on your individual needs.
If you miss your scheduled Denosumab Intas injection, contact your doctor to arrange the injection as soon as possible. The anti-resorptive effects of denosumab are maintained for approximately 6 months after each injection, after which bone turnover begins to increase. Delaying the injection by a few weeks is unlikely to have a significant impact, but longer delays may lead to a partial reversal of the BMD gains. After the missed dose is administered, your subsequent injections should be rescheduled to every 6 months from the date of the most recent injection.
Both denosumab and bisphosphonates (such as alendronate, risedronate, and zoledronic acid) are effective anti-resorptive treatments for osteoporosis, but they differ in several important ways. Denosumab is given as an injection every 6 months, while oral bisphosphonates are taken weekly or monthly (with strict administration requirements including remaining upright and fasting). Denosumab has been shown to produce greater increases in bone mineral density at some skeletal sites compared with oral bisphosphonates. Unlike bisphosphonates, which accumulate in bone and have a prolonged residual effect after stopping, denosumab’s effects are fully reversible, necessitating transition to alternative therapy upon discontinuation. Your doctor will recommend the most appropriate treatment based on your individual risk profile, preferences, and medical history.
References
- European Medicines Agency (EMA). Denosumab Intas – Summary of Product Characteristics. Last updated 2025. Available at: EMA Denosumab Intas EPAR.
- U.S. Food and Drug Administration (FDA). Prolia (denosumab) – Prescribing Information. Amgen Inc. Revised 2024.
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med. 2009;361(8):756–765. doi:10.1056/NEJMoa0809493.
- Bone HG, Wagman RB, Brandi ML, et al. 10 Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results from the Phase 3 Randomised FREEDOM Trial and Open-Label Extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523. doi:10.1016/S2213-8587(17)30138-9.
- Tsourdi E, Zillikens MC, Meier C, et al. Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. J Clin Endocrinol Metab. 2021;106(1):264–281. doi:10.1210/clinem/dgaa756.
- International Osteoporosis Foundation (IOF). IOF-ESCEO Guidelines for the Diagnosis and Management of Osteoporosis in Postmenopausal Women and Men from the Age of 50 Years. Updated 2024.
- National Institute for Health and Care Excellence (NICE). Technology Appraisal TA204: Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women. 2023.
- World Health Organization (WHO). Prevention and Management of Osteoporosis. WHO Technical Report Series No. 921. Geneva: WHO.
- British National Formulary (BNF). Denosumab. National Institute for Health and Care Excellence (NICE). 2025.
- Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density (ADAMO). J Clin Endocrinol Metab. 2012;97(9):3161–3169. doi:10.1210/jc.2012-1569.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in rheumatology, endocrinology, and clinical pharmacology with extensive experience in osteoporosis management and anti-resorptive therapies.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, IOF, NICE).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.